---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-154955"
form_type: "8-K"
ticker: "SEPN"
cik: "0001984086"
company_name: "Septerna, Inc."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:43:09.562335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Septerna and Novo Nordisk collaboration becomes effective after HSR clearance

## Summary
- Collaboration and License Agreement with Novo Nordisk became effective July 1, 2025.
- Early termination of HSR waiting period triggered effectiveness of May 13, 2025 deal.
- Summary of terms previously filed in May 14, 2025 8-K; full agreement to be filed in Q2 10-Q.

## SEC filing metadata
- accession: 0001193125-25-154955
- form_type: 8-K
- ticker: SEPN
- cik: 0001984086
- company_name: Septerna, Inc.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1984086/000119312525154955/0001193125-25-154955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1984086/000119312525154955/d815359d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-154955
- JSON: https://secwatch.observer/filing/0001193125-25-154955.json
- Plain text: https://secwatch.observer/filing/0001193125-25-154955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.